Jering H, Tschesche H
Eur J Biochem. 1976 Jan 15;61(2):453-63. doi: 10.1111/j.1432-1033.1976.tb10039.x.
The reactive-site sequence of a proteinase inhibitor can be written as . . . -P3-P2-P1-P'1-P'2-P'3- . . . , where-P1-P'1-denotes the reactive site. Three semisynthetic homologues have been synthesized of the bovine trypsin-kallikrein inhibitor (Kunitz) with either arginine, phenylalanine or tryptophan in place of the reactive-site residue P1, lysine-15. These homologues correspond to gene products after mutation of the lysine 15 DNA codon to an arginine, phenylalanine or tryptophan DNA codon. Starting from native (virgin) inhibitor, reactive-site hydrolyzed, still active (modified) inhibitor was prepared by chemical and enzymic reactions. Modified inhibitor was then converted into inactive des-Lys15-inhibitor by reaction with carboxypeptidase B. Inactive des-Lys15-inhibitor was reactivated by enzymic replacement of the P1 residue according to Leary and Laskowski, Jr. The introduction of arginine was catalyzed by an inverse reaction with carboxypeptidase B, while phenylalanine or tryptophan were replaced by carboxypeptidase A. The reactivated semisynthetic inhibitors were trapped by complex formation with either trypsin or chymotrypsin. The enzyme - inhibitor complexes were subjected to kinetic-control dissociation, and the semisynthetic virgin inhibitors were isolated. The inhibitory properties of the semisynthetic inhibitors have been investigated against bovine trypsin and chymotrypsin and against porcine pancreatic kallikrein and plasmin. The homologues with either lysine or arginine in the P1 position are equally good inhibitors of trypsin, plasmin and kallikrein. The Arg-15-homologue is a slightly more effective kallikrein inhibitor than the Lys15-inhibitor. The semisynthetic phenylalanine and tryptophan homologues, however, are weak inhibitors of trypsin and still weaker inhibitors of kallikrein, but are excellent inhibitors of chymotrypsin. Their association constant with chymotrypsin is at least ten times higher than that of native Lys-15-inhibitor. A dramatic specificity change is observed with the phenylalanine and tryptophan homologues, which in contrast to the native inhibitor do not at all inhibit porcine plasmin. Thus, the nature of the P1 residue strongly influences the primary inhibitory specificity of the bovine inhibitor (Kunitz).
蛋白酶抑制剂的活性位点序列可写成……-P3-P2-P1-P'1-P'2-P'3-……,其中-P1-P'1-表示活性位点。已合成了三种牛胰蛋白酶-激肽释放酶抑制剂(Kunitz)的半合成同系物,分别用精氨酸、苯丙氨酸或色氨酸取代活性位点残基P1(赖氨酸-15)。这些同系物对应于赖氨酸15的DNA密码子突变为精氨酸、苯丙氨酸或色氨酸的DNA密码子后的基因产物。从天然(未处理的)抑制剂开始,通过化学和酶促反应制备活性位点水解但仍具活性(修饰的)抑制剂。然后通过与羧肽酶B反应将修饰的抑制剂转化为无活性的去Lys15-抑制剂。根据Leary和Laskowski, Jr.的方法,通过酶促置换P1残基使无活性的去Lys15-抑制剂重新活化。精氨酸的引入由与羧肽酶B的逆反应催化,而苯丙氨酸或色氨酸则由羧肽酶A取代。重新活化的半合成抑制剂通过与胰蛋白酶或糜蛋白酶形成复合物而被捕获。酶-抑制剂复合物进行动力学控制解离,分离出半合成的未处理抑制剂。研究了半合成抑制剂对牛胰蛋白酶和糜蛋白酶以及对猪胰激肽释放酶和纤溶酶的抑制特性。P1位置为赖氨酸或精氨酸的同系物对胰蛋白酶、纤溶酶和激肽释放酶的抑制效果相同。Arg-15-同系物作为激肽释放酶抑制剂比Lys15-抑制剂稍有效。然而,半合成的苯丙氨酸和色氨酸同系物是胰蛋白酶的弱抑制剂,对激肽释放酶的抑制作用更弱,但却是糜蛋白酶的优良抑制剂。它们与糜蛋白酶的缔合常数比天然Lys-15-抑制剂至少高十倍。观察到苯丙氨酸和色氨酸同系物有显著的特异性变化,与天然抑制剂不同,它们根本不抑制猪纤溶酶。因此,P1残基的性质强烈影响牛抑制剂(Kunitz)的主要抑制特异性。